Taxotere is linked to the permanent hair loss disease alopecia which effects hair loss of the head and body, loss of eyebrows, loss of eyelashes, loss of facial hair, and loss of pubic hair. Permanent hair loss or alopecia is not reversible.
Taxotere is the brand-name for docetaxel, an infusion (IV) chemotherapy drug that has been widely used to treat female breast cancer patients since 1996 across the U.S.
Taxotere is used to stop the growth and spread of cancer cells in the body. Like many chemotherapy drugs, Taxotere works by destroying living cells to help destroy cancer cells and stop cancer growth.
Women treated with Taxotere allegedly face a lifetime of baldness, humiliation, lowered self esteem and quality of life.
Temporary hair loss is a common side effect of cancer treatment, and some may even say a small price to pay to conquer the disease. Patients have a right to know the risks and side effects.
Failure to warn about the side effects of Taxotere.
According to the non profit organization breastcancer.org as of January 2018, there are more than 3.1 million U.S. women with a history of breast cancer in the U.S. including women currently being treated and women who have finished treatment.
Taxotere is made by Sanofi-Aventis, the fifth largest pharmaceutical company by sales (2013). Oncologists use Taxotere generically known as docetaxel in a vast majority of breast cancer patients. Up to 75% of these women will receive Taxotere.
Taxotere is delivered intravenously, typically once every 3 weeks throughout the treatment plan. It was hailed as an effective and convenient form of chemotherapy. Yet Taxotere allegedly carries a higher rate of permanent hair loss.
Taxotere is known to cause hair follicles to die. The manufacturer of Taxotere was allegedly aware of the risks yet continued to market the process.
Taxotere pursued decades of deception keeping facts of the serious known side effect of permanent hair loss (alopecia) from doctors and their patients.
Sanofi-Aventis sold Taxotere for more than 20 years failing to warn doctors and their patients of the serious potential side effect of permanent hair loss. Drug manufacturer, Sanofi-Aventis allegedly hid these facts and continued to make billions of dollars as they routine marketed docetaxel under the name Taxotere.
FDA warning labels were only added to Taxotere drugs in December 2016.
Studies of Alopecia occurring in Taxotere patients includes:
- Documents from the Sanofi-funded GEICAM 9805 study – which was presented as evidence in an ongoing litigation against Sanofi, reveal that around 9.2% of patients suffered hair loss that lasted more than a decade.
- A 2006 study conducted by the Rock Mountain Cancer Centers found that Taxotere caused 6% of women to suffer permanent alopecia.
- A 2012 study published in the Annals of Oncology indicated of the 20 female participants who received Taxotere, 19 developed permanent hair loss. One participant who was being treated for reoccurring breast cancer had previously undergone chemotherapy with a different drug and had complete hair regrowth, but after using Taxotere, she suffered from permanent hair loss.
Breast cancer patients have the right to know risks of high incidence of side effects.
Permanent alopecia is a disfiguring condition, especially for women. Women living with permanent alopecia after treatment with Taxotere can feel as though you are still battling cancer, and suffer mental anguish. This is unfair and unjust.
Our lawyers are here to help you through this difficult time.